Damora Therapeutics (DMRA) Return on Equity (2020 - 2026)

Damora Therapeutics (DMRA) has 7 years of Return on Equity data on file, last reported at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity changed 0.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (changed 0.0% YoY), and the FY2025 full-year result was 0.02%, down 1.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.01%, up from 0.02% in the prior quarter.
• Across five years, Return on Equity topped out at 0.0% in Q2 2025 and bottomed at 0.02% in Q4 2025.
• The 5-year median for Return on Equity is 0.01% (2022), against an average of 0.01%.
• The widest annual swing landed in 2023, when Return on Equity slipped 1 bps; it then gained 1 bps in 2024.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2022, then dropped by 22 bps to 0.01% in 2023, then surged by 51 bps to 0.01% in 2024, then plunged by 202 bps to 0.02% in 2025, then jumped by 63 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.02% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.

Peer Comparison